While pharmaceutical companies and medical device firms know that working together is a vital part of doing business, they “live in 2 different world in many ways,” Minnetronix co-founder Dirk Smith said last week at the annual Drug Delivery Partnerships conference. From development timelines to regulatory approval pathways, it can sometimes seem like pharma and medtech companies are […]
Baxter to pay $18m to settle moldy IV plant case
Baxter (NYSE:BAX) agreed to pay $18 million to settle criminal and civil cases stemming from a North Carolina sterile intravenous solution plant where mold was found in air filters. The agreement includes penalties and forfeitures of some $16 million and another $2.2 million to settle a civil qui tam lawsuit with the U.S. Justice Dept. Whistleblower Christopher Wall, […]
Baxter to put up $625m for Claris Injectables generics biz
Baxter (NYSE:BAX) said today that acquired Claris Lifesciences (BOM:533288) subsidiary Claris Injectables for $625 million. The deal is expected to close in the 2nd half of next year. Deerfield, Ill.-based Baxter said it plans to pay for the acquisition with cash on hand, debt or a combination. Baxter anticipates launching 7 to 9 new products […]
Baxter releases infusion pump programming software
Baxter (NYSE:BAX) launched its Sigma Spectrum Safety Management System this week at the American Society of Health-System Pharmacists meeting. The infusion pump system consists of an analytics software and a suite of remote professional services for cyber-security monitoring. The Deerfield, Ill.-based company said its Sigma Spectrum system was developed to minimize infusion pump programming risks, […]
Ivenix CEO Randle looks to reboot the infusion pump
Ivenix CEO Stuart Randle began his foray into drug pump delivery systems at Baxter in 1988, when he led the company’s effort to develop the 1st needle-free IV system. More than 20 years later, when he was approached about the corner office at Ivenix, Randle revisited the infusion pump industry and saw that the technology had not kept up […]
Baxter buys stake in Ocular Therapeutix
MassDevice.com +3 | Baxter's CEO reaps $14M, Sapien trial cut short on adverse events, Devices plus drugs pose great potential
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.